proteins candidates Search Results


93
Shanghai Korain Biotech Co Ltd nadh oxidase
Nadh Oxidase, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nadh oxidase/product/Shanghai Korain Biotech Co Ltd
Average 93 stars, based on 1 article reviews
nadh oxidase - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Boster Bio glut4 primary antibody
Glut4 Primary Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glut4 primary antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
glut4 primary antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Proteintech primary anti nupr1 antibody
The primer sequence of 6 genes
Primary Anti Nupr1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary anti nupr1 antibody/product/Proteintech
Average 94 stars, based on 1 article reviews
primary anti nupr1 antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Proteintech rhoa
FIGURE 2 Effect of apatinib treatment on level of <t>RhoA</t> and Rho-associated coiled-coil domain-containing protein kinase mRNAs. Apatinib upregulated RhoA <t>and</t> <t>ROCK</t> II mRNAs relative to the vehicle (P < 0.001) but downregulated GRAF3 (P < 0.001) in the mid-aorta. Apatinib had no effect on level of ROCK I mRNAs between vehicle and treatment groups (n ¼ 8 in each group). P less than 0.05. ROCK, Rho-associated coiled-coil domain-containing protein kinase.
Rhoa, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhoa/product/Proteintech
Average 93 stars, based on 1 article reviews
rhoa - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
Proteintech anti tusc4 antibody
A. Lower <t>TUSC4</t> expression levels was found in both luminal and basal types of breast cancer cell lines, while non-transformed breast cell lines (HMEC, MCF-10A and MCF-12A) exhibited higher TUSC4 level.
Anti Tusc4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti tusc4 antibody/product/Proteintech
Average 92 stars, based on 1 article reviews
anti tusc4 antibody - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Proteintech tusc3
A. Lower <t>TUSC4</t> expression levels was found in both luminal and basal types of breast cancer cell lines, while non-transformed breast cell lines (HMEC, MCF-10A and MCF-12A) exhibited higher TUSC4 level.
Tusc3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tusc3/product/Proteintech
Average 93 stars, based on 1 article reviews
tusc3 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Boster Bio anti tmem16a antibody
FIGURE 1 | Molecular expression levels of <t>TMEM16A</t> in LV. (A) TMEM16A mRNA expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (B) Traditional western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (C) Simple western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA).
Anti Tmem16a Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti tmem16a antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
anti tmem16a antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
Proteintech fus antibody
FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via <t>FUS</t> in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an <t>anti-FUS</t> <t>antibody</t> in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.
Fus Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fus antibody/product/Proteintech
Average 91 stars, based on 1 article reviews
fus antibody - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

90
Glaxo Smith candidate recombinant fusion protein vaccine m72
FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via <t>FUS</t> in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an <t>anti-FUS</t> <t>antibody</t> in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.
Candidate Recombinant Fusion Protein Vaccine M72, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/candidate recombinant fusion protein vaccine m72/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
candidate recombinant fusion protein vaccine m72 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Dezhou Deyao Pharmaceutical Co Ltd nb-arc-tpr candidate immune receptor proteins
FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via <t>FUS</t> in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an <t>anti-FUS</t> <t>antibody</t> in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.
Nb Arc Tpr Candidate Immune Receptor Proteins, supplied by Dezhou Deyao Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nb-arc-tpr candidate immune receptor proteins/product/Dezhou Deyao Pharmaceutical Co Ltd
Average 90 stars, based on 1 article reviews
nb-arc-tpr candidate immune receptor proteins - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Novavax Inc recombinant spike-protein-based vaccine candidate with matrix-m adjuvant
FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via <t>FUS</t> in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an <t>anti-FUS</t> <t>antibody</t> in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.
Recombinant Spike Protein Based Vaccine Candidate With Matrix M Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant spike-protein-based vaccine candidate with matrix-m adjuvant/product/Novavax Inc
Average 90 stars, based on 1 article reviews
recombinant spike-protein-based vaccine candidate with matrix-m adjuvant - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Protein Sciences Inc rha vaccine candidate
FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via <t>FUS</t> in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an <t>anti-FUS</t> <t>antibody</t> in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.
Rha Vaccine Candidate, supplied by Protein Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rha vaccine candidate/product/Protein Sciences Inc
Average 90 stars, based on 1 article reviews
rha vaccine candidate - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


The primer sequence of 6 genes

Journal: BMC Medical Genomics

Article Title: Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma

doi: 10.1186/s12920-023-01785-4

Figure Lengend Snippet: The primer sequence of 6 genes

Article Snippet: In brief, the tissue sections were incubated with a primary Anti-NUPR1 antibody (dilution 1:100; catalog number 15056-1-AP, Proteintech, China) and subsequently processed using the appropriate detection system.

Techniques: Sequencing

Single cell sequencing analysis of ERSRGs-signature. ( A ) tSNE clustering colored by groups. ( B ) The annotation of clusters based on marker analysis. mRNA distribution of BAK1 ( C ), EIF2AK3 ( D ), MBTPS2 ( E ), NUPR1 ( F ), RHBDD2 ( G ) and VCP ( H ) after tSNE dimensionality reduction. ( I ) Differential expression of ERSRGs in the different cell clusters

Journal: BMC Medical Genomics

Article Title: Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma

doi: 10.1186/s12920-023-01785-4

Figure Lengend Snippet: Single cell sequencing analysis of ERSRGs-signature. ( A ) tSNE clustering colored by groups. ( B ) The annotation of clusters based on marker analysis. mRNA distribution of BAK1 ( C ), EIF2AK3 ( D ), MBTPS2 ( E ), NUPR1 ( F ), RHBDD2 ( G ) and VCP ( H ) after tSNE dimensionality reduction. ( I ) Differential expression of ERSRGs in the different cell clusters

Article Snippet: In brief, the tissue sections were incubated with a primary Anti-NUPR1 antibody (dilution 1:100; catalog number 15056-1-AP, Proteintech, China) and subsequently processed using the appropriate detection system.

Techniques: Sequencing, Marker, Quantitative Proteomics

Validation of the expression levels of ERSRGs in LUAD. The mRNA expression of BAK1 ( A ), EIF2AK3 ( B ), MBTPS2 ( C ), NUPR1 ( D ), RHBDD2 ( E ) and VCP ( F ) in LUAD patients from Nantong tumor hospital. N = 8, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ( G ) The protein expression of BAK1, EIFAK3, MBTPS2, RHBDD2 and VCP in HPA

Journal: BMC Medical Genomics

Article Title: Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma

doi: 10.1186/s12920-023-01785-4

Figure Lengend Snippet: Validation of the expression levels of ERSRGs in LUAD. The mRNA expression of BAK1 ( A ), EIF2AK3 ( B ), MBTPS2 ( C ), NUPR1 ( D ), RHBDD2 ( E ) and VCP ( F ) in LUAD patients from Nantong tumor hospital. N = 8, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ( G ) The protein expression of BAK1, EIFAK3, MBTPS2, RHBDD2 and VCP in HPA

Article Snippet: In brief, the tissue sections were incubated with a primary Anti-NUPR1 antibody (dilution 1:100; catalog number 15056-1-AP, Proteintech, China) and subsequently processed using the appropriate detection system.

Techniques: Biomarker Discovery, Expressing

Expression analysis of NUPR1 at transcription and translation Levels. Representative images ( A ) and quantification ( B ) of NUPR1 in intratumoral and peritumoral fractions through immunohistochemistry staining (N = 6). MRNA ( C ) and protein expression ( D & E ) of NUPR1 in cell lines (N = 3). ( F ) Cell viability assessed through CCK8 assays between saline and trifluoperazine subgroups (N = 6). ( G ) Representative images and results of cell counting from the Transwell invasion assay (N = 3). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Journal: BMC Medical Genomics

Article Title: Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma

doi: 10.1186/s12920-023-01785-4

Figure Lengend Snippet: Expression analysis of NUPR1 at transcription and translation Levels. Representative images ( A ) and quantification ( B ) of NUPR1 in intratumoral and peritumoral fractions through immunohistochemistry staining (N = 6). MRNA ( C ) and protein expression ( D & E ) of NUPR1 in cell lines (N = 3). ( F ) Cell viability assessed through CCK8 assays between saline and trifluoperazine subgroups (N = 6). ( G ) Representative images and results of cell counting from the Transwell invasion assay (N = 3). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: In brief, the tissue sections were incubated with a primary Anti-NUPR1 antibody (dilution 1:100; catalog number 15056-1-AP, Proteintech, China) and subsequently processed using the appropriate detection system.

Techniques: Expressing, Immunohistochemistry, Staining, Saline, Cell Counting, Transwell Invasion Assay

FIGURE 2 Effect of apatinib treatment on level of RhoA and Rho-associated coiled-coil domain-containing protein kinase mRNAs. Apatinib upregulated RhoA and ROCK II mRNAs relative to the vehicle (P < 0.001) but downregulated GRAF3 (P < 0.001) in the mid-aorta. Apatinib had no effect on level of ROCK I mRNAs between vehicle and treatment groups (n ¼ 8 in each group). P less than 0.05. ROCK, Rho-associated coiled-coil domain-containing protein kinase.

Journal: Journal of Hypertension

Article Title: Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension

doi: 10.1097/hjh.0000000000003060

Figure Lengend Snippet: FIGURE 2 Effect of apatinib treatment on level of RhoA and Rho-associated coiled-coil domain-containing protein kinase mRNAs. Apatinib upregulated RhoA and ROCK II mRNAs relative to the vehicle (P < 0.001) but downregulated GRAF3 (P < 0.001) in the mid-aorta. Apatinib had no effect on level of ROCK I mRNAs between vehicle and treatment groups (n ¼ 8 in each group). P less than 0.05. ROCK, Rho-associated coiled-coil domain-containing protein kinase.

Article Snippet: The membranes were blocked with 5% skim milk, and immunoblotted with the following primary antibodies: RhoA (1 : 1000, 10749–1-AP, Protein-tech, Wuhan, China), ROCK I (1 : 1000, ab134181, Abcam, Cambridge, UK), ROCK II (1 : 20000, ab125025, Abcam), MLCP (1 : 1000, ab32519, Abcam), endothelin A receptor (ETA, 1 : 900, ab85163, Abcam), and collagen I (Col I, 1 : 500, ab6308, Abcam).

Techniques:

FIGURE 3 Effect of apatinib on expression of proteins in the RhoA/Rho-associated coiled-coil domain-containing protein kinase signaling pathway. Apatinib upregu- lated expression of RhoA and ROCK II proteins but had no significant effect on ROCK I expression in all groups (n ¼ 8 in each group). P less than 0.05. ROCK, Rho-associated coiled-coil domain-containing protein kinase.

Journal: Journal of Hypertension

Article Title: Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension

doi: 10.1097/hjh.0000000000003060

Figure Lengend Snippet: FIGURE 3 Effect of apatinib on expression of proteins in the RhoA/Rho-associated coiled-coil domain-containing protein kinase signaling pathway. Apatinib upregu- lated expression of RhoA and ROCK II proteins but had no significant effect on ROCK I expression in all groups (n ¼ 8 in each group). P less than 0.05. ROCK, Rho-associated coiled-coil domain-containing protein kinase.

Article Snippet: The membranes were blocked with 5% skim milk, and immunoblotted with the following primary antibodies: RhoA (1 : 1000, 10749–1-AP, Protein-tech, Wuhan, China), ROCK I (1 : 1000, ab134181, Abcam, Cambridge, UK), ROCK II (1 : 20000, ab125025, Abcam), MLCP (1 : 1000, ab32519, Abcam), endothelin A receptor (ETA, 1 : 900, ab85163, Abcam), and collagen I (Col I, 1 : 500, ab6308, Abcam).

Techniques: Expressing

A. Lower TUSC4 expression levels was found in both luminal and basal types of breast cancer cell lines, while non-transformed breast cell lines (HMEC, MCF-10A and MCF-12A) exhibited higher TUSC4 level.

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: A. Lower TUSC4 expression levels was found in both luminal and basal types of breast cancer cell lines, while non-transformed breast cell lines (HMEC, MCF-10A and MCF-12A) exhibited higher TUSC4 level.

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Expressing, Transformation Assay

A. TUSC4 knockdown reduced BRCA1 foci formation after IR, while control cells didn't have such effect (NT). γ-H2AX indicated the efficiency of irradiation.

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: A. TUSC4 knockdown reduced BRCA1 foci formation after IR, while control cells didn't have such effect (NT). γ-H2AX indicated the efficiency of irradiation.

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Knockdown, Control, Irradiation

A. Knockdown of TUSC4 didn't significantly change the cell cycle distribution of U2OS cells compared to control cells. G1, G2/M and S phases cells were indicated by percentage of total cell numbers.

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: A. Knockdown of TUSC4 didn't significantly change the cell cycle distribution of U2OS cells compared to control cells. G1, G2/M and S phases cells were indicated by percentage of total cell numbers.

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Knockdown, Control

A. TUSC4 knockdown increased ubiquitination level of BRCA1 compared to control cells (After MG132 enrichment for ubiquitination).

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: A. TUSC4 knockdown increased ubiquitination level of BRCA1 compared to control cells (After MG132 enrichment for ubiquitination).

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Knockdown, Ubiquitin Proteomics, Control

A. Colony formation assay indicated that normal U2OS cells are not sensitive to PARP inhibitor Olaparib (1μm) but TUSC4-knockdown cells exhibited increased sensitivity to Olaparib, the colonies were significantly reduced after the treatment (p<0.05).

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: A. Colony formation assay indicated that normal U2OS cells are not sensitive to PARP inhibitor Olaparib (1μm) but TUSC4-knockdown cells exhibited increased sensitivity to Olaparib, the colonies were significantly reduced after the treatment (p<0.05).

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Colony Assay, Knockdown

Tumorigenicity of Orthotopically Implanted Control and  TUSC4-overexpression  MDA-MB-231 cells 5×10 6 cells from MDA-AB-231 control and two independent TUSC4-overexpressing MDA-AB-231 cell lines (TUSC4 #7 and TUSC4 #13) were injected per mouse into mammary tumor sizes were analyzed.

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: Tumorigenicity of Orthotopically Implanted Control and TUSC4-overexpression MDA-MB-231 cells 5×10 6 cells from MDA-AB-231 control and two independent TUSC4-overexpressing MDA-AB-231 cell lines (TUSC4 #7 and TUSC4 #13) were injected per mouse into mammary tumor sizes were analyzed.

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Control, Injection

Tumorigenicity of Orthotopically Implanted Control and  TUSC4-Knockdown  MCF10A cells 1×10 7 cells from MCF-10A control and two independent TUSC4-knockdown MCF-10A cell lines (TUSC4 #1 and TUSC4 #4) were injected per mouse into mammary fat pads glands of 6-week-old female nude mice. Each cell line was injected in five different mice, and tumor sizes were analyzed.

Journal: Cancer research

Article Title: TUSC4 functions as a tumor suppressor by regulating BRCA1's stability via the E3 ubiquitination pathway

doi: 10.1158/0008-5472.CAN-14-2315

Figure Lengend Snippet: Tumorigenicity of Orthotopically Implanted Control and TUSC4-Knockdown MCF10A cells 1×10 7 cells from MCF-10A control and two independent TUSC4-knockdown MCF-10A cell lines (TUSC4 #1 and TUSC4 #4) were injected per mouse into mammary fat pads glands of 6-week-old female nude mice. Each cell line was injected in five different mice, and tumor sizes were analyzed.

Article Snippet: An anti-TUSC4 antibody was purchased from Proteintech (10157-1-AP), an anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), and anti-Flag M2 (F3165) and anti-β-actin (A2066) antibodies were purchased from Sigma.

Techniques: Control, Injection

FIGURE 1 | Molecular expression levels of TMEM16A in LV. (A) TMEM16A mRNA expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (B) Traditional western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (C) Simple western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA).

Journal: Frontiers in physiology

Article Title: TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload.

doi: 10.3389/fphys.2022.897619

Figure Lengend Snippet: FIGURE 1 | Molecular expression levels of TMEM16A in LV. (A) TMEM16A mRNA expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (B) Traditional western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA). (C) Simple western blot results of TMEM16A protein expression level in LV (n = 3 mice in each group per time point, RM two-way ANOVA).

Article Snippet: Briefly, total protein was separated on 10% SDS-PAGE, transferred onto a PVDF membrane and blotted with the following primary antibodies separately: Anti-TMEM16A antibody (ACL-011, Alomone labs) for protein extracted from mouse heart, Anti-TMEM16A antibody (BA3464-2, Boster) for endogenous human TMEM16A protein in HUVECs, AntiTMEM16A antibody (ab53212, Abcam) for overexpressed mouse TMEM16A protein induced by lentivirus in HUVECs, and Anti-β-actin antibody (CST).

Techniques: Expressing, Western Blot, Simple Western

FIGURE 2 | Ito in LVMs. (A) Recordings show the effects of T16Ainh-A01 (30 μM) or 4-AP (5 mM) on Ito in LVMs. (B) Recordings show the effects of Anti-TMEM16A antibody (1:200) or 4-AP (5 mM) on Ito in LVMs. (C) I-V relations of T16Ainh-A01 sensitive current and Anti-TMEM16A antibody sensitive current (n = 4 cells in each group, two-way ANOVA). (D) I-V relation of 4-AP sensitive current (n = 4 cells in each group, two-way ANOVA).

Journal: Frontiers in physiology

Article Title: TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload.

doi: 10.3389/fphys.2022.897619

Figure Lengend Snippet: FIGURE 2 | Ito in LVMs. (A) Recordings show the effects of T16Ainh-A01 (30 μM) or 4-AP (5 mM) on Ito in LVMs. (B) Recordings show the effects of Anti-TMEM16A antibody (1:200) or 4-AP (5 mM) on Ito in LVMs. (C) I-V relations of T16Ainh-A01 sensitive current and Anti-TMEM16A antibody sensitive current (n = 4 cells in each group, two-way ANOVA). (D) I-V relation of 4-AP sensitive current (n = 4 cells in each group, two-way ANOVA).

Article Snippet: Briefly, total protein was separated on 10% SDS-PAGE, transferred onto a PVDF membrane and blotted with the following primary antibodies separately: Anti-TMEM16A antibody (ACL-011, Alomone labs) for protein extracted from mouse heart, Anti-TMEM16A antibody (BA3464-2, Boster) for endogenous human TMEM16A protein in HUVECs, AntiTMEM16A antibody (ab53212, Abcam) for overexpressed mouse TMEM16A protein induced by lentivirus in HUVECs, and Anti-β-actin antibody (CST).

Techniques:

FIGURE 5 | Molecular expression levels of TMEM16A in HUVECs. (A) TMEM16A mRNA expression level in HUVECs (n = 3–4). (B) Western blot results of TMEM16A protein expression level in HUVECs (n = 3–5). *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA and unpaired t-test.

Journal: Frontiers in physiology

Article Title: TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload.

doi: 10.3389/fphys.2022.897619

Figure Lengend Snippet: FIGURE 5 | Molecular expression levels of TMEM16A in HUVECs. (A) TMEM16A mRNA expression level in HUVECs (n = 3–4). (B) Western blot results of TMEM16A protein expression level in HUVECs (n = 3–5). *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA and unpaired t-test.

Article Snippet: Briefly, total protein was separated on 10% SDS-PAGE, transferred onto a PVDF membrane and blotted with the following primary antibodies separately: Anti-TMEM16A antibody (ACL-011, Alomone labs) for protein extracted from mouse heart, Anti-TMEM16A antibody (BA3464-2, Boster) for endogenous human TMEM16A protein in HUVECs, AntiTMEM16A antibody (ab53212, Abcam) for overexpressed mouse TMEM16A protein induced by lentivirus in HUVECs, and Anti-β-actin antibody (CST).

Techniques: Expressing, Western Blot

FIGURE 6 | Effect of TMEM16A on migration in HUVECs. (A) Wound healing assay results of HUVECs transfected with siRNANC or siRNAMix, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 5—8 in each group per time point). (B) Wound healing assay results of HUVECs transfected with TMNC

Journal: Frontiers in physiology

Article Title: TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload.

doi: 10.3389/fphys.2022.897619

Figure Lengend Snippet: FIGURE 6 | Effect of TMEM16A on migration in HUVECs. (A) Wound healing assay results of HUVECs transfected with siRNANC or siRNAMix, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 5—8 in each group per time point). (B) Wound healing assay results of HUVECs transfected with TMNC

Article Snippet: Briefly, total protein was separated on 10% SDS-PAGE, transferred onto a PVDF membrane and blotted with the following primary antibodies separately: Anti-TMEM16A antibody (ACL-011, Alomone labs) for protein extracted from mouse heart, Anti-TMEM16A antibody (BA3464-2, Boster) for endogenous human TMEM16A protein in HUVECs, AntiTMEM16A antibody (ab53212, Abcam) for overexpressed mouse TMEM16A protein induced by lentivirus in HUVECs, and Anti-β-actin antibody (CST).

Techniques: Migration, Wound Healing Assay, Transfection

FIGURE 7 | Effect of TMEM16A on angiogenesis in HUVECs. (A,C) Tube formation assay results of HUVECs transfected with siRNANC or siRNAMix, or TMNC, or TMOE, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 3–9). (B,D) Endothelial cell spheroids sprouting assay results of HUVECs transfected with siRNANC or siRNAMix, or TMNC, or TMOE, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 3–5). *p < 0.05 compared with siRNANC or TMNC under the same treatment, #p < 0.05 and ##p < 0.01 compared with vehicle (PBS) in the same cell type, two-way ANOVA.

Journal: Frontiers in physiology

Article Title: TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload.

doi: 10.3389/fphys.2022.897619

Figure Lengend Snippet: FIGURE 7 | Effect of TMEM16A on angiogenesis in HUVECs. (A,C) Tube formation assay results of HUVECs transfected with siRNANC or siRNAMix, or TMNC, or TMOE, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 3–9). (B,D) Endothelial cell spheroids sprouting assay results of HUVECs transfected with siRNANC or siRNAMix, or TMNC, or TMOE, and treated with vehicle (PBS), or VEGF (30 ng/mL), or AngII (1 μM) separately (n = 3–5). *p < 0.05 compared with siRNANC or TMNC under the same treatment, #p < 0.05 and ##p < 0.01 compared with vehicle (PBS) in the same cell type, two-way ANOVA.

Article Snippet: Briefly, total protein was separated on 10% SDS-PAGE, transferred onto a PVDF membrane and blotted with the following primary antibodies separately: Anti-TMEM16A antibody (ACL-011, Alomone labs) for protein extracted from mouse heart, Anti-TMEM16A antibody (BA3464-2, Boster) for endogenous human TMEM16A protein in HUVECs, AntiTMEM16A antibody (ab53212, Abcam) for overexpressed mouse TMEM16A protein induced by lentivirus in HUVECs, and Anti-β-actin antibody (CST).

Techniques: Tube Formation Assay, Transfection

FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via FUS in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an anti-FUS antibody in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.

Journal: Frontiers in cell and developmental biology

Article Title: LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6.

doi: 10.3389/fcell.2021.701628

Figure Lengend Snippet: FIGURE 3 | Nucleus lncRNA NORAD associates with HDAC6 via FUS in ox-LDL-treated HUVECs. (A) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs. (B) Potential binding sites for FUS in lncRNA NORAD analyzed by ENCORI. (C) Representative images of Co-IP using an anti-FUS antibody in HUVECs. Rabbit IgG was used as negative control. (D) Representative images of WB following RAP performed by probe-targeting lncRNA NORAD in HUVECs transfected with control shRNA or shRNA-targeting lncRNA NORAD under ox-LDL treatment. In the bar graph, the protein level of HDAC6 was quantified and normalized by input. shRNA; shNORAD, shRNA-targeting lncRNA NORAD; NC, negative control; siCtrl, control siRNA; siFUS, FUS siRNA (***p < 0.001 vs. other groups). N = 3.

Article Snippet: Subsequently, about 300 μg of protein was incubated with 1 μg of FUS antibody (Proteintech, United States) and 25 μl of protein A/G magnetic beads for immunoprecipitation at 4◦C overnight.

Techniques: Binding Assay, Co-Immunoprecipitation Assay, Negative Control, Transfection, Control, shRNA